[EN] ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) [FR] DERIVES D'ACIDE 1H-INDOL-3-YL GLYOXYLIQUE A SUBSTITUTION ARYLE, ARYLOXY ET ALKYLOXY EN TANT QU'INHIBITEURS DE L'INHIBITEUR DE L'ACTIVATEUR DU PLASMINOGENE-1 (PAI-1)
[EN] ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) [FR] DERIVES D'ACIDE 1H-INDOL-3-YL GLYOXYLIQUE A SUBSTITUTION ARYLE, ARYLOXY ET ALKYLOXY EN TANT QU'INHIBITEURS DE L'INHIBITEUR DE L'ACTIVATEUR DU PLASMINOGENE-1 (PAI-1)
Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
申请人:Wyeth
公开号:US20040138283A1
公开(公告)日:2004-07-15
Compounds of formula I are provided:
1
wherein:
R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.
Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
申请人:Wyeth
公开号:US07259182B2
公开(公告)日:2007-08-21
Compounds of formula I are provided:
wherein:
R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.
Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
申请人:Jennings Dalton Lee
公开号:US20070259922A1
公开(公告)日:2007-11-08
Compounds of formula I are provided:
wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.